To determine whether one such mechanism is related to heparanase presence and activity in the nucleus, we first assessed whether myeloma patients in the HPSE-high group (from the MMRF CoMMpass database, Figure 2B) had elevated PTEN as compared to patients in the HPSE-low group. This evidence concerns the gene PTEN and plasma cell myeloma.